Celltrion Inc., a South Korean biotech firm, saw its foreign ownership increase to 24.5% by end-June, driven by robust earnings and expanded investor relations activities abroad. The company reported record-high Q2 operating profit and sales estimates.
Celltrion has completed the cancellation of approximately 490,000 treasury shares worth about 100 billion won, reducing its total issued shares. The company plans to continue its shareholder return policy, aiming for a cumulative 2 trillion won in share cancellations this year, alongside its mid-to-long-term growth strategies.
Celltrion announced on the 26th its plan to strengthen competitiveness by introducing AI in new drug development and manufacturing. The company aims to significantly shorten the drug development period, which typically takes over 10 years, by utilizing AI for candidate substance discovery and verification.
SEOUL, May 12 (Yonhap) -- South Korea's Celltrion Inc. said Tuesday it acquired ...
SEOUL, May 6 (Yonhap) -- Celltrion Inc., a major South Korean biopharmaceutical ...
Celltrion Inc., a leading South Korean biopharmaceutical company, announced plans to repurchase 100 billion won (US$68 million) worth of its own shares to enhance shareholder value and support the company's valuation amid external uncertainties stemming from Middle East tensions. The company also cancelled treasury shares worth 1.8 trillion won last week under a broader shareholder return initiative.
